Silodosin
FDA-approved product (capsule, oral), marketed as Rapaflo, Silodosin.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Benign prostatic hyperplasia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Alpha-adrenoreceptor antagonists
- FDA pharmacologic class
- alpha-Adrenergic Blocker FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA44.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli41.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis56.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Silodosin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia
NCT02106182 · start 2014-01-02
Registered record
- Registry ID
- NCT02106182
- Conditions
- Nocturia; Benign Prostatic Hyperplasia
- Interventions
- Silodosin; Laboratory tests; 3-days voiding diary; 12 weeks
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2014-01-02
- Completion
- 2016-08-01
- Enrolment
- 135
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNocturia; Benign Prostatic HyperplasiaInterventionSilodosin; Laboratory tests; 3-days voiding diary; 12 weeksPhasePhase 4Registry statusCompletedSafety and Efficacy of Silodosin in the Treatment of Premature Ejaculation
NCT02581826 · start 2013-10
Registered record
- Registry ID
- NCT02581826
- Conditions
- Premature Ejaculation
- Interventions
- Silodosin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2013-10
- Completion
- 2016-12
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPremature EjaculationInterventionSilodosin; PlaceboPhasePhase 2Registry statusUnknownThe Changes of Urine Growth Factors Level
NCT06282731 · start 2013-05-31
Registered record
- Registry ID
- NCT06282731
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Silodosin
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Completed
- Start
- 2013-05-31
- Completion
- 2017-04-27
- Enrolment
- 74
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic HyperplasiaInterventionSilodosinPhaseEarly phase 1Registry statusCompletedDifferential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy
NCT01560091 · start 2012-03
Registered record
- Registry ID
- NCT01560091
- Conditions
- Kidney Stones
- Interventions
- silodosin; Extra-corporeal shock wave lithotripsy; Tamsulosin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Withdrawn
- Start
- 2012-03
- Completion
- 2013-02
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKidney StonesInterventionsilodosin; Extra-corporeal shock wave lithotripsy; TamsulosinPhasePhase 3Registry statusWithdrawnEfficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones
NCT01533389 · start 2011-10
Registered record
- Registry ID
- NCT01533389
- Conditions
- Ureteral Stone
- Interventions
- Silodosin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2011-10
- Completion
- 2012-08
- Enrolment
- 114
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUreteral StoneInterventionSilodosin; PlaceboPhasePhase 4Registry statusCompletedEffectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia
NCT01757769 · start 2011-05
Registered record
- Registry ID
- NCT01757769
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Silodosin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2011-05
- Completion
- 2013-08
- Enrolment
- 1,036
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic HyperplasiaInterventionSilodosinPhasePhase 4Registry statusCompletedEfficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder
NCT01228370 · start 2011-04
Registered record
- Registry ID
- NCT01228370
- Conditions
- Neurogenic Bladder; Voiding Dysfunction
- Interventions
- silodosin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2011-04
- Completion
- 2012-01
- Enrolment
- 95
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNeurogenic Bladder; Voiding DysfunctionInterventionsilodosinPhasePhase 4Registry statusCompletedStudy of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)
NCT01259531 · start 2010-12
Registered record
- Registry ID
- NCT01259531
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Silodosin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2010-12
- Completion
- 2011-09
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic HyperplasiaInterventionSilodosinPhasePhase 4Registry statusCompletedSafety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH
NCT01260129 · start 2010-10
Registered record
- Registry ID
- NCT01260129
- Conditions
- Benign Prostatic Hypertrophy
- Interventions
- Silodosin; Silodosin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2010-10
- Completion
- 2011-10
- Enrolment
- 424
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic HypertrophyInterventionSilodosin; SilodosinPhasePhase 4Registry statusCompletedClinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy
NCT01435954 · start 2010-08
Registered record
- Registry ID
- NCT01435954
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Early combination therapy; Delayed combination therapy
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2010-08
- Completion
- 2011-03
- Enrolment
- 13,551
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic HyperplasiaInterventionEarly combination therapy; Delayed combination therapyPhaseNot recordedRegistry statusCompletedStudy of Silodosin to Facilitate Passage of Urinary Stones
NCT01144949 · start 2010-06
Registered record
- Registry ID
- NCT01144949
- Conditions
- Ureteral Calculi; Kidney Stones; Urolithiasis
- Interventions
- silodosin; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2010-06
- Completion
- 2012-07
- Enrolment
- 239
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUreteral Calculi; Kidney Stones; UrolithiasisInterventionsilodosin; placeboPhasePhase 2Registry statusCompletedEstablishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence
NCT01390870 · start 2009-05
Registered record
- Registry ID
- NCT01390870
- Conditions
- Prostatic Hyperplasia
- Interventions
- 5ARI or AB or Combination Therapy (5ARI + AB)
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2009-05
- Completion
- 2010-09
- Enrolment
- 400
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstatic HyperplasiaIntervention5ARI or AB or Combination Therapy (5ARI + AB)PhaseNot recordedRegistry statusCompletedA Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia
NCT00793819 · start 2009-01
Registered record
- Registry ID
- NCT00793819
- Conditions
- Nocturia; Prostatic Hyperplasia
- Interventions
- silodosin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-01
- Completion
- 2009-10
- Enrolment
- 215
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNocturia; Prostatic HyperplasiaInterventionsilodosinPhasePhase 2Registry statusCompletedUse of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
NCT00740779 · start 2008-09
Registered record
- Registry ID
- NCT00740779
- Conditions
- Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome
- Interventions
- Silodosin 8 mg; Placebo; Silodosin 4 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-09
- Completion
- 2009-10
- Enrolment
- 153
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAbacterial Chronic Prostatitis/Chronic Pelvic Pain SyndromeInterventionSilodosin 8 mg; Placebo; Silodosin 4 mgPhasePhase 2Registry statusCompletedEvaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH
NCT00359905 · start 2006-05
Registered record
- Registry ID
- NCT00359905
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Silodosin; Tamsulosin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-05
- Completion
- 2008-01
- Enrolment
- 1,228
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic HyperplasiaInterventionSilodosin; Tamsulosin; PlaceboPhasePhase 3Registry statusCompleted